Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 18 years~* HIV infected, diagnosed with chronic hepatitis or compensated cirrhosis by hepatitis C virus (both anti-HCV antibodies and HCV RNA levels detectable in serum) not previously treated.~* Women of child-bearing age: negative pregnancy test~* Ability to understand and sign a written consent form~Exclusion Criteria:~* Previous interferon treatment~* Pregnancy or breastfeeding~* Acute or chronic hepatitis B infection (positivity for hepatitis B surface antigen or plasma DNA)~* Creatinine clearance \< 50 ml/min, according to Cockcroft-Gault~* Decompensated liver disease~* History of organ transplantation~* Concomitant treatment with immunomodulators or didanosine~* Alcohol abuse or use of other recreational drugs~* History of severe psychiatric conditions~* Autoimmune diseases~* Inability to understand and sign a written consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- G 2/3 (Type: EXPERIMENTAL): Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.

Based on this trial design, predict the completion outcome and termination type (if applicable).